Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor

Molecular Pharmacology

Volumn 63, Issue 1, 2003, Pages 211-223

  Yin, Donghua ^a   He, Yali ^b   Perera, Minoli A ^a   Hong, Seoung Soo ^b   Marhefka, Craig ^b   Stourman, Nina ^b   Kirkovsky, Leonid ^b   Miller, Duane D ^b   Dalton, James T ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; BICALUTAMIDE; CYTOSOL RECEPTOR; LIGAND; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGONIST; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASSAY; CELL CULTURE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; KIDNEY CELL; MALE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROSTATE; RADIOASSAY; RAT; RECEPTOR AFFINITY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION;

ANILIDES; ANIMALS; CELLS, CULTURED; FLUTAMIDE; HAPLORHINI; IMIDAZOLES; IMIDAZOLIDINES; LIGANDS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TRAIL MAKING TEST;

EID: 0037222170     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.1.211     Document Type: Article

References (36)

1. Bagatell CJ and Bremner WJ (1996) Androgens in men - Uses and abuses. N Engl J Med 334:707-714.
2. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 389:753-758.
3. Cockshott ID, Cooper KJ, Sweetmore DS, Blacklock NJ, and Denis L (1990) The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol 18:10-17.
4. Dalton JT, Mukherjee A, Zhu Z, Kirkovsky L, and Miller DD (1998) Discovery of nonsteroidal androgens. Biochem Biophys Res Commun 244:1-4.
5. Edwards JP, Higuchi RI, Winn DT, Pooley CL, Caferro TR, Hamann LG, Zhi L, Marschke KB, Goldman ME, and Jones TK (1999) Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one. Bioorg Med Chem Lett 9:1003-1008.
6. Edwards JP, West SJ, Pooley CL, Marschke KB, Farmer LJ, and Jones TK (1998) New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett 8:745-750.
7. Ekena K, Katzenellenbogen JA, and Katzenellenbogen BS (1998) Determinants of ligand specificity of estrogen receptor-α: Estrogen versus androgen discrimination. J Biol Chem 273:693-699.
8. Glen AT, Hughes LR, Morris JJ, and Taylor PJ (1986) Structure-activity relationships among nonsteroidal antiandrogens, in Proceedings of the Third Sci-RSC Medicinal Chemistry Symposium (Lambert RW ed) pp 345-361, Royal Society of Chemistry, London.
9. Hamann LG, Mani NS, Davis RL, Wang XN, Marschke KB, and Jones TK (1999) Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). J Med Chem 42:210-212.
10. Hamann LG, Winn DT, Pooley CL, Tegley CM, West SJ, Farmer LJ, Zhi L, Edwards JP, Marschke KB, Mais DE, et al. (1998) Nonsteroidal progesterone receptor antagonists based on a conformationally-restricted subseries of 6-aryl-1,2-dihydro-2,2,4-trimethylquinolines. Bioorg Med Chem Lett 8:2731-2736.
11. He Y, Yin D, Perera M, Kirkovsky L, Stourman N, Li W, Dalton J, and Miller D (2002) Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgen receptor. Eur J Med Chem 37:619-634.
12. Higuchi RI, Edwards JP, Caferro TR, Ringgenberg JD, Kong JW, Hamann LG, Arienti KL, Marschke KB, Davis RL, Farmer LJ, et al. (1999) 4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: Potent, nonsteroidal androgen receptor agonists. Bioorg Med Chem Lett 9:1335-1340.
13. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, and Brinkmann AO (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation and subcellular localization. Mol Endocrinol 5:1396-1404.
14. Kallio PJ, Janne OA, and Palvimo JJ (1994) Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor. Endocrinology 134:998-1001.
15. Kemppainen JA, Langley E, Wong CI, Bobseine K, Kelce WR, and Wilson EM (1999) Distinguishing androgen receptor agonists and antagonists: Distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 13:440-454.
16. Kirkovsky L, Mukherjee A, Yin D, Dalton JT, and Miller DD (2000) Chiral nonsteroidal affinity ligands for the androgen receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. J Med Chem 43:581-590.
17. Kuil CW, Berrevoets CA, and Mulder E (1995) Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J Biol Chem 270:27569-27576.
18. Kuil CW and Mulder E (1994) Mechanism of antiandrogen action: Conformational changes of the receptor. Mol Cell Endocrinol 102:R1-5.
19. Kuil CW and Mulder E (1995) Effects of androgens and antiandrogens on the conformation of the androgen receptor. Ann N Y Acad Sci 761:351-354.
20. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, et al. (2000) Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171.
21. McLeod DG (1993) Antiandrogenic drugs. Cancer 71:1046-1049.
22. Mitlak BH and Cohen FJ (1999) Selective estrogen receptor modulators: A look ahead. Drugs 57:653-663.
23. Morris JJ, Hughes LR, Glen AT, and Taylor PJ (1991) Non-steroidal antiandrogens. Design of novel compounds based on an infrared study of the dominant conformation and hydrogen-bonding properties of a series of anilide antiandrogens. J Med Chem 34:447-455.
24. Mukherjee A, Kirkovsky L, Yao XT, Yates RC, Miller DD, and Dalton JT (1996) Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 26:117-122.
25. Mukherjee A, Kirkovsky LI, Kimura Y, Marvel MM, Miller DD, and Dalton JT (1999) Affinity labeling of the androgen receptor with nonsteroidal chemoaffinity ligands. Biochem Pharmacol 58:1259-1267.
26. Neri R, Peets E, and Watnick A (1979) Anti-androgenicity of flutamide and its metabolite Sch 16423. Biochem Soc Trans 7:565-569.
27. Neumann F (1982) Pharmacology and clinical use of antiandrogens: A short review. Ir J Med Sci 151:61-70.
28. Teutsch G, Goubet F, Battmann T, Bonfils A, Bouchoux F, Cerede E, Gofflo D, Gaillard-Kelly M, and Philibert D (1994) Non-steroidal antiandrogens: Synthesis and biological profile of high-affinity ligands for the androgen receptor. J Steroid Biochem Mol Biol 48:111-119.
29. Tsai MJ and O'Malley BW (1994) Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451-486.
30. Tucker H, Crook JW, and Chesterson GJ (1988) Nonsteroidal antiandrogens. Synthesis and structure-activity relationships of 3-substituted derivatives of 2-hydroxypropionanilides. J Med Chem 31:954-959.
31. Weryha G, Pascal-Vigneron V, Klein M, and Leclere J (1999) Selective estrogen receptor modulators. Curr Opin Rheumatol 11:301-306.
32. Wu FC (1992) Testicular steroidogenesis and androgen use and abuse. Baillieres Clin Endocrinol Metab 6:373-403.
33. Zhi L, Tegley CM, Kallel EA, Marschke KB, Mais DE, Gottardis MM, and Jones TK (1998) 5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: A novel class of nonsteroidal human progesterone receptor agonists. J Med Chem 41:291-302.
34. Zhi L, Tegley CM, Marschke KB, and Jones TK (1999) Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. Bioorg Med Chem Lett 9:1009-1012.
35. Zhi L, Tegley CM, Pio B, West SJ, Marschke KB, Mais DE, and Jones TK (2000) Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines. Bioorg Med Chem Lett 10:415-418.
36. Zhou ZX, Wong CI, Sar M, and Wilson EM (1994) The androgen receptor: An overview. Recent Prog Horm Res 49:249-274.